Abstract:HIV-1 based lentiviral viruses are considered powerful and versatile gene therapy vectors to deliver therapeutic genes to patients with hereditary or acquired diseases. These vectors can efficiently transduce a variety of cell types when dividing or non-dividing to provide permanent delivery and long-term gene expression. Demand for scalable manufacturing protocols able to generate enough high titre vector for widespread use of this technology is increasing and considerable efforts to improve vector production cost-effectively, is ongoing. Current methods for LV production mainly use transient transfection of producer cell lines. Cells can be grown at scale, either in 2D relying on culturing producer cells in multi-tray flask cell culture factories or in roller bottles or can be adapted to grow in 3D suspensions in large batch fermenters. This suits rapid production and testing of new vector constructs pre-clinically for their efficacy, particle titre and safety. In this study, we sought to improve lentiviral titre over time by testing two alternative commercially available transfection reagents Fugene® 6 and Genejuice® with the commonly used polycation, polyethyleneimine. Our aim was to identify less cytotoxic transfection reagents that could be used to generate LV particles at high titre past the often used 72 hour period when vector is usually collected before producer cell death is caused due to post transfection cytotoxicity. We show that LV could be produced in extended culture using Genejuice® and even by transfected cells in glass flasks in suspension. Because this delivery agent is less toxic to 293T producer cells, following optimisation of transfection we found that LV can be harvested for more than 10 days at high titre. Using our protocol, titres of 10 9 TU/ml and 10 8 TU/ml were routinely reached via traditional monolayer conditions or suspension cultures, respectively. We propose, this simple change in vector production enables large volumes of high titre vector to be produced, cost effectively for non-clinical in vivo and in vitro applications or for more stringent downstream clinical grade vector purification.

Optimized Methods for Preparation of Viron Producing Package Cell Line

An improved HAdV-41 E1B55K-expressing 293 cell line for packaging fastidious adenovirus.

[Sorting of Packaging Cells for Retroviral Vector Carrying Green Fluorescent Gene and Viral Titer Determination].

Process Optimization for the Rapid Production of Adenoviral Vectors for Clinical Trials in a Disposable Bioreactor System.

Optimization of packaging the HIV-1 pseudotyped virus

Preparation of High-titer Lentivirus and Optimization of the Infection Conditions for Human Primary T cells

Optimization of Production Procedure of Replicating Recombinant Live Vaccinia Virus Vector-based Vaccine

[Preparation of the High-Titer Retroviral Viruses for Transducting PDGF-A Gene].

Increase Retroviral Titers by Repeated Supernatant Infection between the Amphotropic and Ectropic Retrovirus Producer Cells

Production of Lentiviral Vectors in Suspension Cells Using Low Proportion of Supercoiled Circular Plasmid DNA

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform

Process optimization for the rapid production of Enterovirus 71

Transient Transfection Methods for Preparation of High‐Titer Retroviral Supernatants

Establishing 293T suspension cultrue for lentiviral vector production in a stirred bioreactor

Development of an HSV-1 production process involving serum-reduced culturing and bead-to-bead transfer

Process Improvement of Adeno-Associated Virus Production

An optimized method for high-titer lentivirus preparations without ultracentrifugation

Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture

Optimization of lentiviral vector production using polyethylenimine-mediated transfection.

Establishment of a novel stable human suspension packaging cell line producing ecotropic retroviral MLV(PVC-211) vectors efficiently transducing murine hematopoietic stem and progenitor cells

The Optimal Conditions to Improve Retrovirus-Mediated Transduction Efficiency to NIH 3T3 Cells